Precigen Inc. Reports Strong Second‑Quarter 2026 Financial Results, Highlights Rapid Growth of PAPZIMEOS

Precigen Inc. (Nasdaq: PGEN), a commercial‑stage biopharmaceutical company focused on precision medicines, announced its financial results for the second quarter of 2026 on August 4 , 2026. The company reported net revenue of $53.1 million for the quarter, more than doubling the prior‑quarter figure. This increase reflects accelerating commercial momentum and broad adoption of its flagship product, PAPZIMEOS, in the United States.

Key Financial Highlights

  • Net revenue: $53.1 million (Q2 2026).
  • Quarterly profitability: Achieved for the first time, driven largely by PAPZIMEOS sales.
  • Cash position: Cash, cash equivalents, and investments totaled $38.7 million as of June 30 , 2026.
  • Cash flow outlook: The company expects to reach cash‑flow break‑even by the end of 2026, supported by continuing PAPZIMEOS revenue and its robust cash reserves.

Commercial Momentum for PAPZIMEOS

  • Patient enrollment: Over 500 patients have been registered through Precigen’s patient hub across major centers and community practices.
  • FDA exclusivity: The FDA granted PAPZIMEOS a seven‑year market exclusivity period, providing long‑term protection against competition.
  • Market adoption: The product is gaining traction as a first‑line standard of care for adults with recurrent respiratory papillomatosis (RRP), a disease caused by human papillomavirus (HPV) types 6 and 11.

Strategic Focus

  • Global expansion: Precigen plans to expand PAPZIMEOS beyond the United States and into pediatric populations.
  • Pipeline development: The company is advancing PRGN‑2009, a therapy targeting HPV‑driven cancers, with an update expected by year‑end.
  • Platform validation: PAPZIMEOS demonstrates the AdenoVerse platform’s capability to target HPV‑associated diseases, reinforcing the company’s position in the precision medicine space.

Market Commentary

A price target of $14.00 was reiterated by HC Wainwright & Co., indicating continued analyst confidence in Precigen’s growth prospects. The company’s market capitalization stands at approximately $2.24 billion, with a 52‑week high of $6.70 and a 52‑week low of $1.70. Precigen’s price‑to‑earnings ratio is currently negative at –5.22, reflecting its ongoing investment in commercial expansion and pipeline development.

Corporate Governance

Recent filings indicate executive activity:

  • The Chief Operating Officer, Rutul Shah, sold $219,518 of company stock.
  • Other insiders have filed Form 4 and Form 144 disclosures, though no material impact on the company’s operations was reported.

Precigen’s CEO, Helen Sabzevari, highlighted the company’s “historic second quarter” and emphasized its foundation for future growth. The company will hold a conference call at 4:30 PM ET on the same day to discuss the results in detail.